Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Alex N. Pokov"'
Publikováno v:
Thrombosis and Haemostasis. 111:3-7
SummaryThe recently published, largest trial with cangrelor, the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX, suggested that the experimental agent significantly reduced the rate of stent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012ab262bd7688212a558f33fd3919b8
https://doi.org/10.1160/th13-08-0631
https://doi.org/10.1160/th13-08-0631
Autor:
Charles H. Hennekens, Wendy R. Schneider, David L. DeMets, Victor L. Serebruany, Scott Hetzel, Alex N. Pokov, Henning Schröder
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 15:344-348
Background: We performed the first test in humans of whether aspirin at clinically relevant doses increases nitric oxide (NO) formation. Methods: Seventy primary prevention patients with metabolic syndrome were randomly assigned to 81 mg, 162.5 mg, 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b932541bc38ff3cebcf491ed5ee7b23a
https://doi.org/10.1177/1074248410375091
https://doi.org/10.1177/1074248410375091
Publikováno v:
Clinical Therapeutics. 30:249-259
Clopidogrel, aspirin (ASA), and the fixed-dose combination of extended-release dipyridamole and ASA (ER-DP+ASA) are widely used in post-stroke regimens.This study compared serial changes in multiple biomarkers of platelet activation with ER-DP+ASA an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c45310743ee0cbbb6c1e4e3cf00fe7
https://doi.org/10.1016/j.clinthera.2008.02.006
https://doi.org/10.1016/j.clinthera.2008.02.006
Autor:
Dan Atar, Victor L. Serebruany, François Lespérance, Alex I. Malinin, Nancy Frasure-Smith, Louis T. van Zyl, Alex N. Pokov
Publikováno v:
Neuropsychopharmacology. 32:2369-2374
There is an increasing body of evidence suggesting that selective serotonin reuptake inhibitors exhibit clinical benefit beyond treating depression, by simultaneously inhibiting platelet activity. We recently demonstrated that escitalopram (ESC), but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b33a27bf88d83ba77c8ecbfc3d448657
https://doi.org/10.1038/sj.npp.1301355
https://doi.org/10.1038/sj.npp.1301355
Autor:
Dan Atar, Victor L. Serebruany, Dominick J. Angiolillo, Alex I. Malinin, Umesh Arora, Alex N. Pokov
Publikováno v:
Thrombosis Research. 119:175-181
Introduction Ongoing search for the optimal dosing regimens, and valid concerns that some GPIIb/IIIa inhibitors may cause rebound platelet activation are limiting the use of these agents in patients with acute vascular events. Materials and methods W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb37bbdbbb9e852e717c95655801005
https://doi.org/10.1016/j.thromres.2006.02.004
https://doi.org/10.1016/j.thromres.2006.02.004
Publikováno v:
Expert review of cardiovascular therapy. 13(12)
The optimal utilization of antiplatelet therapy in patients with renal impairment (RI) following acute coronary syndromes (ACS) represents an urgent, unmet and yet unsolved need with regards to the choice of agents, duration of treatment and potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aadd75e2c8f110527e7fe47a2b5c329
https://pubmed.ncbi.nlm.nih.gov/26513059
https://pubmed.ncbi.nlm.nih.gov/26513059
Autor:
Alex N. Pokov, Jean Francois Tanguay, Alex I. Malinin, Charles H. Hennekens, Michael Miller, David R. Lowry, Victor L. Serebruany
Publikováno v:
The American Journal of Cardiology. 97:1332-1336
We investigated whether, in primary prevention patients with metabolic syndrome, statins affect the platelet protease-activated receptor-1 (PAR-1) thrombin receptor by performing serial measurements of its activity and the antigen expression level by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871573a4bc39ec444db738fa25424c3f
https://doi.org/10.1016/j.amjcard.2005.11.058
https://doi.org/10.1016/j.amjcard.2005.11.058
Autor:
Alex N. Pokov, Alex I. Malinin, Aviv Takserman, Jean Francois Tanguay, Victor L. Serebruany, François Lespérance, Louis T. van Zyl, Dan Atar
Publikováno v:
Journal of Clinical Psychopharmacology. 26:172-177
Clinical depression has been identified as an independent risk factor for increased mortality during follow-up in patients suffered from acute coronary events, whereas increased platelet activity has been proposed as one of the mechanisms for this as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a0b4596cd99efd21dc5d7135cb3108f
https://doi.org/10.1097/01.jcp.0000204047.76286.6e
https://doi.org/10.1097/01.jcp.0000204047.76286.6e
Autor:
Bernd Jilma, Dan Atar, Alex N. Pokov, Victor L. Serebruany, Alex I. Malinin, D. F. Hanley, Wendy C. Ziai
Publikováno v:
Cerebrovascular Diseases. 21:98-105
Background: Although controversial, the phenomenon of aspirin resistance (AR) has been correlated in some small studies with poor clinical outcomes in patients with coronary artery disease. Even less is known regarding the role of AR in the poststrok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eff433f255af2608e79e9cf8e8e8207e
https://doi.org/10.1159/000090207
https://doi.org/10.1159/000090207
Autor:
Wendy C. Ziai, Alex N. Pokov, D. F. Hanley, Mark J. Alberts, Alex I. Malinin, Deepak L. Bhatt, Victor L. Serebruany
Publikováno v:
Stroke. 36:2289-2292
Background and Purpose— Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study. To determine whether clop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0dbc4d149945b6001046785142d4755
https://doi.org/10.1161/01.str.0000181081.09262.e1
https://doi.org/10.1161/01.str.0000181081.09262.e1